Raymond Miller

发表

Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

Kaori Ito, B. Corrigan, Qinying Zhao, 2011, Alzheimer's & Dementia.

How Modeling and Simulation Have Enhanced Decision Making in New Drug Development

B. Corrigan, Raymond Miller, J. Werth, 2005, Journal of Pharmacokinetics and Pharmacodynamics.

Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial

E. Antman, R. Giugliano, E. Braunwald, 2018, Circulation.

Nonlinear Mixed Effects Modeling of Single Dose and Multiple Dose Data for an Immediate Release (IR) and a Controlled Release (CR) Dosage Form of Alprazolam

Raymond Miller, M. Hossain, T. Ludden, 1997, Pharmaceutical Research.

Comparative Population Pharmacokinetic‐Pharmacodynamic Analysis for Piroxicam‐β‐Cyclodextrin and Piroxicam

Raymond Miller, Chuanpu Hu, Jenny H. Zheng, 2000, Journal of clinical pharmacology.

Population Pharmacokinetics and Dose–Exposure Proportionality of Edoxaban in Healthy Volunteers

Raymond Miller, O. Yin, 2014, Clinical Drug Investigation.

Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial

Raymond Miller, Takako Shimizu, M. Karlsson, 2016, Clinical Pharmacokinetics.

A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin

Raymond Miller, D. Wesche, S. Chapel, 2010, Clinical pharmacokinetics.

Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism--the Hokusai-VTE phase 3 study.

Raymond Miller, M. Karlsson, S. Jönsson, 2015, British journal of clinical pharmacology.

Model‐Supported Development of CS‐8635: A Fixed‐Dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide

Raymond Miller, Helen Moore, S. Rohatagi, 2013, Clinical pharmacology in drug development.

Pharmacokinetic/Pharmacodynamic Modeling in Drug Research and Development

Hartmut Derendorf, Gerald Rhodes, Raymond Miller, 2000, Journal of clinical pharmacology.

Joint modeling of dizziness, drowsiness, and dropout associated with pregabalin and placebo treatment of generalized anxiety disorder

Matthew M. Hutmacher, Bill Frame, Raymond Miller, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

Mixed effects modeling of weight change associated with placebo and pregabalin administration

Raymond Miller, B. Frame, S. Beal, 2007, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetic modeling and simulation for assessing renal impairment effect on the pharmacokinetics of mirogabalin

Raymond Miller, O. Yin, K. Truitt, 2016, Journal of clinical pharmacology.

Exposure‐response analysis of pregabalin add‐on treatment of patients with refractory partial seizures

Brian Corrigan, Bill Frame, B. Corrigan, 2003, Clinical pharmacology and therapeutics.

Modeling Dropout From Adverse Event Data: Impact of Dosing Regimens Across Pregabalin Trials in the Treatment of Generalized Anxiety Disorder

Raymond Miller, M. Hutmacher, B. Frame, 2011, Journal of clinical pharmacology.

Modelling overdispersion and Markovian features in count data

Mats O. Karlsson, Raymond Miller, Elodie L. Plan, 2009, Journal of Pharmacokinetics and Pharmacodynamics.

An alternative method for population pharmacokinetic data analysis under noncompliance

Raymond Miller, Pankaj Gupta, Matthew M. Hutmacher, 2008, Journal of Pharmacokinetics and Pharmacodynamics.

Population pharmacokinetic‐pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment

Raymond Miller, D. Kang, Saeheum Song, 2014, Journal of clinical pharmacology.

Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation

Raymond Miller, O. Yin, Kimura Tetsuya, 2014, European Journal of Clinical Pharmacology.

Modeling Longitudinal Daily Seizure Frequency Data From Pregabalin Add‐On Treatment

Mats O Karlsson, Jae Eun Ahn, Raymond Miller, 2012, Journal of clinical pharmacology.

Population Pharmacokinetics of Clinafloxacin in Healthy Volunteers and Patients with Infections

Raymond Miller, R. Miller, B. Frame, 2001, Clinical pharmacokinetics.

A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data

Lynn McFadyen, Kenneth G. Kowalski, Matthew M. Hutmacher, 2003, Journal of Pharmacokinetics and Pharmacodynamics.

Model‐based Drug Development

W Ewy, B. Corrigan, Raymond Miller, 2007, Clinical pharmacology and therapeutics.

Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

Raymond Miller, S. Jönsson, U. Simonsson, 2015, Journal of clinical pharmacology.

Phenytoin auto-induction.

Raymond Miller, R. Miller, M. Chetty, 1998, Therapeutic drug monitoring.

Exposure-Response Relationship to Assess the Risk of Neutropenia in Patients With Hepatocellular Carcinoma (HCC) Treated With Tivantinib

Raymond Miller, G. Abbadessa, H. Kastrissios, 2012 .

A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin

Raymond Miller, D. Wesche, S. Chapel, 2010, Clinical pharmacokinetics.

Population pharmacokinetics

Raymond Miller, O. Yin, 2022, Atkinson's Principles of Clinical Pharmacology.

Edoxaban population pharmacokinetics and exposure–response analysis in patients with non-valvular atrial fibrillation

Raymond Miller, O. Yin, Kimura Tetsuya, 2014, European Journal of Clinical Pharmacology.

Modeling Longitudinal Daily Seizure Frequency Data From Pregabalin Add‐On Treatment

Jae Eun Ahn, Raymond Miller, E. Plan, 2012, Journal of clinical pharmacology.